ProPhase Labs Inc(NASDAQ:PRPH) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Earnings per share were $-0.06.
ProPhase Labs Inc (PRPH) made into the market gainers list on Wednesdays trading session with the shares advancing 3.43% or 0.06 points. Due to strong positive momentum, the stock ended at $1.81, which is also near the day’s high of $1.83. The stock began the session at $1.81 and the volume stood at 6,490 shares. The 52-week high of the shares is $2.24 and the 52 week low is $1.05. The company has a current market capitalization of $31 M and it has 1,70,80,776 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Dec 8, 2015, Mark S Leventhal (director) purchased 14,248 shares at $1.51 per share price.Also, On Jun 5, 2015, Ted William Karkus (director officer 10% owner ) purchased 200,000 shares at $1.30 per share price.
ProPhase Labs Inc. is a manufacturer marketer and distributor of a range of homeopathic and health products. The Company is also engaged in the research and development of potential over-the-counter (OTC) drugs natural base health products along with supplements personal care and cosmeceutical products. The Company’s primary business is the manufacture distribution marketing and sale of OTC cold remedy products to consumers through national chain regional specialty and local retail stores. The Company also manufactures markets and distributes an organic cough drop and a Vitamin C supplement Organix and performs contract manufacturing services of cough drop dietary supplements and other OTC cold remedy products for third parties. The Company’s flagship brand is Cold-EEZE Cold Remedy and its principal product is Cold-EEZE Cold Remedy zinc gluconate lozenges. Its product pipeline also includes Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray.